home All News open_in_new Full Article

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab […]


today 1 week ago attach_file Politics

attach_file Economics
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Transport
attach_file Other
attach_file Events
attach_file Culture
attach_file Economics
attach_file Economics
attach_file Other
attach_file Politics
attach_file Events
attach_file Culture
attach_file Culture
attach_file Politics
attach_file Economics
attach_file Other


ID: 3757659910
Add Watch Country

arrow_drop_down